Posts by Sandra Ansanay-Alex
Debiopharm and Merck invest in artificial intelligence
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, and M Ventures, the strategic, corporate venture capital arm of Merck, and Omnes Capital invested CHF 15.5 million in French startup Iktos By 2025, one in two drugs is expected to be discovered and developed using artificial intelligence. Iktos is a French…
Read MoreEFI-Lake Geneva Ventures and Yellowstone Holding AG invest CHF 3,5 million in Medyria
Medyria’s PyCath aims to be the only device on the market with pressure and blood flow velocity sensing for the invasive diagnosis of ischemic heart conditions. Medyria AG, is a Medtech company leader in blood flow velocity sensing. The start-up based in Winterthur recently launched the development of the PyCath a novel microcatheter for…
Read MoreSOPHiA GENETICS and Agilent Partner
SOPHiA GENETICS, a Lausanne-based cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent, a US-based company providing measuring instruments for chemical analysis, life sciences, and diagnostics, to offer a comprehensive solution for cancer analysis. Through the partnership, the SOPHiA DDM™ Platform will be integrated with Agilent’s new Research…
Read MoreGeNeuro raises €25 million for its treatment against long COVID
GeNeuro develops timelimab, an antibody that showed promising results in treating inflammatory symptoms for long COVID patients GeNeuro, a Geneva-based biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19 (PASC, (PASC, post-COVID or long COVID), announced the signature…
Read MoreThree Jura start-ups awarded with the DayOne Tech accelerator prize
The Jura branch of the Swiss Innovation Park Basel Area is home to 28 companies and institutions, including ten in Medtech. Three of them just received an innovation prize. “We have set up an acceleration and coaching programme with people from the industry who will accompany each of the start-ups,” explains Florian Sanner,…
Read MoreDebiopharm expands its oncology pipeline
The Lausanne-based biotech company has obtained global rights from a Novo Nordisk molecule and plans to take the compound forward in overcoming resistant tumor types. Debiopharm announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk. FT-3171…
Read MoreRaphaël Conz is the New Head of Department for Economic Promotion and Innovation in the canton of Vaud
Raphaël Conz is also BioAlps’ vice-president. For many years, he has worked to promote the attractiveness and the reputation of the Swiss Health Valley The State Council of the Canton of Vaud has appointed Raphaël Conz Head of the Department for the Promotion of the Economy and Innovation. He will fill his new position…
Read MoreMedistri invests CHF 8 million in Domdidier
The largest independent sterilisation company in Europe invests to expand its plant in Domdidier, in the canton of Fribourg. On 29 November 2022, Medistri has been granted its building permit for the construction of an extension and realization of new facilities. This expansion will allow Medistri SA to develop and increase its production at…
Read MoreOculis Announces US public listing on Nasdaq
A Swiss Health Valley success story! Oculis goes public. Oculis Holding AG (“Oculis”), based at EPFL Innovation Park in Lausanne, is a global biopharmaceutical company purposefully driven to save sight and improve eye care. On 3 March 2023, it announced its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition…
Read MoreComphya receives approval for first pilot clinical trial in Australia
A swissmade neuromodulator to treat erectile dysfunction starts clinical trials in Australia Comphya SA, developer of the first neuromodulator to treat erectile dysfunction (ED), announced today that Australian regulatory authorities (Human Research Ethics Committees (HREC) and Therapeutic Goods Administration (TGA)) have approved the pilot clinical trial for CaverSTIM in patients undergoing prostatectomy. This will…
Read More